J.-C. Schwartz, J.-M. Lecomte, C. Caussé
Sleep Medicine; Volume 40, Supplement, Page e297
2017-12-01
https://www.sciencedirect.com/science/article/pii/S1389945717313059
Pitolisant, the first potent and highly selective Histamine H3-receptor antagonist/inverse agonist in clinics, activating the histaminergic neurons, demonstrated its efficacy over 7-8 weeks in reducing Excessive Daytime Sleepiness(Lancet Neurol. 2013) and cataplexy attacks (Lancet Neurol. 2017) in adult narcoleptic patients (NP) with or without cataplexy. We compared the anti-cataplectic efficacy results in different phase II and III Randomized Clinical Trials (RCT).